Health Condition 1: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: The patients who underwent HSCT with allogeneic matched sibling donor from December, 2008 to May, 2019 will be included in retrospective arm. Patients, who will undergo HSCT from June, 2019 onwards will be included in prospective arm.
Exclusion criteria
Exclusion criteria: Unrelated, Haplomatched or mismatched patient donor pairs will not be enrolled for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association of Next generation sequencing of Vitamin D receptor (VDR) gene polymorphisms in patients and donors with acute graft versus host disease.Timepoint: From date of transplant to day 100 post transplant. | — |
Secondary
| Measure | Time frame |
|---|---|
| Association of Next generation sequencing of Vitamin D receptor (VDR) gene polymorphisms in patients and donors with transplant related mortality.Timepoint: 1 year post transplant;Association of Next generation sequencing of Vitamin D receptor (VDR) gene polymorphisms in patients and donors with overall survival.Timepoint: 1 year post transplant;Association of Next generation sequencing of Vitamin D receptor (VDR) gene polymorphisms in patients and donors with relapse free survival.Timepoint: 1 year post transplant;Correlation of VDR polymorphisms with vitamin (Vit.) D namely serum 25-hydoxyvitamin D3 and 1,25-dihydroxyvitamin D3 levels pre transplantation and the effect of VDR polymorphisms on the normalization of Vit D levels post supplementationTimepoint: Pretransplant and 4 months from Vit. D supplementation.;Immunomodulatory effect of Vit. D on Th1 Th2 cell subsets along with cytokines in the peripheral blood cytokines post HSCT and its correlation with graft versus host disease.Timepoint: Day 100 post transplant;Immunomodulatory effect of Vit. D on the expression of the HLA gene in the patient post HSCT and its correlation with graft versus host disease.Timepoint: 1 year post transplant | — |
Countries
India
Contacts
Public ContactNavin Khattry
Tata Memorial Centre Advance Centre for Treatment, Research and Education in Cancer
Outcome results
None listed